NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript April 30, 2024 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03. NEO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the NeoGenomics First Quarter 2024 Financial […]
Fourth Quarter Revenue Increased 12% to $156 million;Full Year Revenue Increased 16% to $592 millionFORT MYERS, Fla. (BUSINESS WIRE) NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 resul.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript February 20, 2024 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.01. NEO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the NeoGenomics Fourth Quarter and Full […]
FT. MYERS, Fla., January 02, 2024 NeoGenomics will participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco and will present on Monday, Jan. 8, 8:15 p.m. ET.